←
Ankeet S. Bhatt, MD, MBA, ScM2,074 posts
Ankeet S. Bhatt, MD, MBA, ScM avatar✓

Ankeet S. Bhatt, MD, MBA, ScM ✓

@ankeetbhatt

Cardiologist @kpnorcal | Adj. Prof. @StanfordMed | Prior @MassGenBrigham | Advisor @OpenEvidence | Trials + Care Delivery Innovation | Tweet≠endorse

◷ Joined June 2018▧ 153 Photos and videos
OpenEvidence avatar
⟳ Ankeet S. Bhatt, MD, MBA, ScM retweeted
OpenEvidence@OpenEvidence·Nov 16

The drug that saved @DavidFajgenbaum's life has been on pharmacy shelves for decades. It was approved for kidney transplants. He nearly died of Castleman disease and had been told there was nothing left to try. Thousands of diseases have no FDA-approved treatment. For some of them, the answer may already be sitting in a pharmacy. Nobody has run the trial. @EveryCure, the nonprofit he co-founded, exists to run these trial. Starting today, we’re working with them. OpenEvidence will help evaluate repurposing hypotheses, connect each program with the few physicians who actually treat the disease, and bring trial results back to the point of care when they land. Many of these are generic drugs. No one has a commercial reason to study them. That is exactly why a nonprofit has to.

Post attachment
Journal of Cardiac Failure avatar
⟳ Ankeet S. Bhatt, MD, MBA, ScM retweeted
Journal of Cardiac Failure@JCardFail·Nov 10

AI meets Heart Failure in the November issue of JCF 🫀 Our Focus Issue, Artificial Intelligence and Heart Failure: A Critical Juncture, explores the opportunities and challenges of AI in heart failure research and care. Read the full issue: onlinejcf.com/current

Post attachmentPost attachment
Radcliffe Cardiology avatar
⟳ Ankeet S. Bhatt, MD, MBA, ScM retweeted
Radcliffe Cardiology@radcliffeCARDIO·Nov 8

Watch now! Oral NLRP3 inhibitor ruvonoflast cut hsCRP, IL-6 and fibrinogen in obesity over 24 weeks, with no effect on weight or HbA1c and no serious infections. Dr Javed Butler discusses RESOLVE-1 and what comes next for NLRP3 inhibition at #AHA26 🎥 LINK: radc.life/OepTKcme #ScientificSessions26 #NLRP3

1:04
HF Collaboratory avatar
⟳ Ankeet S. Bhatt, MD, MBA, ScM retweeted
HF Collaboratory@hfcollaboratory·Nov 8

🚨 BREAKING NEWS! Dr. Christopher O’Connor has been appointed the new Editor-in-Chief of Circulation: Heart Failure. Congratulations to Dr. O’Connor on this prestigious appointment and this exciting new chapter in cardiovascular research and scientific leadership! #hfc

Post attachmentPost attachment
Women As One avatar
⟳ Ankeet S. Bhatt, MD, MBA, ScM retweeted
Women As One@WomenAs1·Nov 5

Women were more likely to experience improved ejection fraction after heart failure, yet faced higher rates of worsening HF despite this. We must understand sex differences in HF trajectories & ensure that improvements don't impede ongoing care. jacc.org/doi/10.1016/j.jchf.…

Post attachmentPost attachment
Travis Zack MD avatar
⟳ Ankeet S. Bhatt, MD, MBA, ScM retweeted
Travis Zack MD@TravisZack2·Nov 4

OpenEvidence makes it easy to get an evidence-based answer. But the answer is only part of it. The harder skills are knowing what questions to ask in the first place, and understanding WHY that answer is right and how it applies to the patient in front of you. Today we are announcing OE Learn: a platform built for medical education at every stage of training and practice. We’re launching with three tools: 1. Test Prep: a board-style question bank, including image-based questions, spanning USMLE, COMLEX, and specialty and subspecialty boards. 2. Preceptor: a Socratic tutor for case-based learning, tuned to your level of training. 3. Flashcards: spaced repetition mechanisms built on the questions you’ve already asked @OpenEvidence so the answers become a lasting part of your knowledge. In the next phase, we'll add opt-in adaptive learning tools that gauge your proficiency across topics and suggest what to study next, and eventually what questions you should be asking. What else would you like to see on OE Learn?

0:57
Travis Zack MD avatar
⟳ Ankeet S. Bhatt, MD, MBA, ScM retweeted
Travis Zack MD@TravisZack2·Nov 2

What I am most excited about? Everything MSK knows about a tumor genetics now reaches every community clinic in the country.

2:29
Vivien Ho avatar
⟳ Ankeet S. Bhatt, MD, MBA, ScM retweeted
Vivien Ho@VivHo·Oct 22

Thank you to @MSKCancerCenter for being incredible partners with @OpenEvidence in our shared goal to end cancer for life.

2:29
Robert W. Yeh avatar
⟳ Ankeet S. Bhatt, MD, MBA, ScM retweeted
Robert W. Yeh@rwyeh·Oct 9

AI has a lot to offer to medicine. But the scientific traditions of medicine also have a lot to offer AI. @AdamRodmanMD and @BIDMCVFellows Peter Brodeur just led the first clinical trial to evaluate the safety of Google's patient facing tool AMIE. Incredible work!

OpenEvidence avatar
⟳ Ankeet S. Bhatt, MD, MBA, ScM retweeted
OpenEvidence@OpenEvidence·Sep 29

Some of the evidence clinicians need most sits in specialty society journals that few outside the specialty ever see. We've signed an agreement with @Sage_Publishing to bring peer-reviewed research from more than 300 Sage journals into OpenEvidence, including titles from societies in sports medicine, stroke, headache, anesthesia, and diabetes care. As that content comes onto the platform, every answer it informs will cite and link back to the original article.

Post attachment
OpenEvidence avatar
⟳ Ankeet S. Bhatt, MD, MBA, ScM retweeted
OpenEvidence@OpenEvidence·Sep 23

“Medicine is a field where you don't need to squint to see the benefits of AI. It's your mom, it's your dad, it's your sister, it's your brother. And it's the doctors who will care for them in their most vulnerable moments.” Yesterday, during the UN General Assembly, we announced a partnership with @AnthropicAI to make OpenEvidence available free of charge to physicians in low- and middle-income countries, placing life-saving medical AI into the hands of physicians worldwide, regardless of the economics.

Post attachment